9.00am - 5.00pm EST | 6.00am - 2.00pm PST

9:00 am Registration & Virtual Coffee

9:20 am Chairman’s Opening Remarks

9:30 am AO-176, A Highly differentiated Clinical Stage Anti-CD47 Antibody, Demonstrates In vitro Phagocytosis and In vivo Efficacy in Multiple Lymphoma Models


  • AO-176 treatment induces phagocytosis of multiple lymphoma cell lines in vitro
  • AO-176-treatment of mice with established lymphoma xenograft tumors caused tumor shrinkage in multiple models and was well tolerated

10:00 am Are Macrophages Drivers of Therapy Resistance in Acute Myeloid Leukaemia?

  • Mark Williams Lecturer in Cell & Molecular Biology, Glasgow Caledonian University


  • Characterization of macrophage subsets in the bone marrow of AML patients
  • Investigating the contribution of primary monocyte derived macrophages towards resistance to AML therapeutics.
  • Identifying the molecular mechanisms underlying therapy resistance in AML

10.30 am Morning Refreshments & Group Networking

Discovery & Pre-Clinical Development

Utilizing Innovative Pre-Clinical Models to Supercharge Clinical Translation

11:30 am Preclinical Humanised Mouse Models for CD47/Sirpa Targeted Cancer Immunotherapies In Vivo

  • Yasuyuki Saito Associate Professor, Kobe University Graduate School
    of Medicine


  • Human macrophages enhance tumor cell growth in vivo
  • – Anti-human SIRPα antibody inhibit B-cell lymphoma growth in cooperation with Rituximab in vivo.
  • – Anti-human SIRPα antibody alter the function of tumor infiltrating macrophages

12:00 pm Modelling Macrophage Targeting in The TME Using Patient-Derived Tumor Explants


  • Pre-clinical and clinical development of bexmarilimab
  • Breast tumor and ovarian ascites samples -what can they tell us about immune switch
  • Nanostring, scRNA and cytokine multiplexing

Clinical Development

Developing Combination Strategies for Greater Efficacy in Clinical Trials

11:30 am Role of Macrophages in B-Cell Lymphoma: A Clinical Perspective

  • Paolo Strati Assistant Professor Department of Lymphoma & Myeloma & Department of Translational Molecular Pathology, MD Anderson Cancer Center


  • Currently available treatments for B-cell lymphoma affect macrophage function
  • Targeting macrophages may improve the efficacy of currently available treatment for B-cell lymphoma
  • Macrophages may be responsible for CAR T-cell therapy-associated toxicities

12:00 pm TG-1801 is a Novel Bispecific CD19-CD47 Antibody Now In Clinic, Tested as a Single Agent or in Combination With Ublituximab


  • TG-1801 is a Bispecific CD19-CD47 antibody in clinic
  • Preclinical combination data with anti-CD20 antibody (TG-1801) or small molecules are presented

12.30 pm Lunch & Networking

Utilizing Novel Biomarkers to Address Heterogeneity in Macrophage Populations

1:30 pm Redefining the Human Mononuclear System in Health and Disease

  • Fernando Martinez Estrada Lecturer in Immunology, Faculty of Health & Medical Sciences, Honorary Senior Research Associate, University of Surrey, University of Oxford


  • To date we lack a marker to unify mononuclear phagocytes in humans or that informs us about their origin
  • Here, we reassess human blood through t lineage receptors and define CSF1R as the first sensitive and reproducible pan-phagocyte lineage marker, to identify and enumerate all conventional monocytes, and the myeloid dendritic cells.
  • Blood assessment of CSF1R+ cells opens a developmental window to the Mononuclear Phagocyte System in transit from bone marrow to tissues, supports isolation and phenotypic characterization, identifies novel cell types, and singles out CSF1R inhibition as therapeutic target in COVID-19 and other diseases

2:00 pm Development of MK-4830 (anti-ILT4 mAb) to Target Immunosuppressive Myeloid Cells for the Treatment of Human Malignancies


  • MK-4830 is a fully human monoclonal antibody that targets ILT4 and blocks its binding to cognate ligands
  • ILT4-blockade by MK-4830 alters the phenotype and function of myeloid-derived suppressor cells
  • MK-4830 treatment induced tumor growth inhibition of a human cancer cell line in a humanized mouse model system
  • MK-4830 and pembrolizumab combination therapy provides clinical benefit to patients enrolled in MK- 4830-001 Phase 1b study

2:30 pm In vivo visualization of Macrophages in Ocular Oncology

  • Shelley Boyd President & CEO, Translatum Medicus inc, Tracery Ophthalmics inc


  • Melanocytic tumours in the eye can be benign or highly malignant, with many classified as “indeterminate” presenting a diagnostic challenge to clinicians
  • Tumour associated macrophages (TAMs) are reported in histopathological specimens of choroidal melanoma and are absent in nevi
  • We are focused on developing novel image acquisition methods, image based biomarkers, and advanced computing for the visualization of TAMs in the living eye

Reprogramming Macrophages to Supercharge the Anti-Tumor Response in Patients

1:30 pm PY314: Targeting Trem2 in CPI Resistant Cancers


  • Trem2 is widely expressed in infiltrating macrophages multiple solid tumors.
  • PY314 is a monoclonal antibody that depletes targeted macrophages via ADCC/ADCP
  • PY314 active in multiple preclinical CPI resistant models
  • Clinical trial in progress evaluating PY314 alone and in combination with pembrolizumab

2:00 pm Modifying Immunosuppressive Macrophages To Immune Stimulatory To Enhance Anti- Tumor Immune Activity

  • Juho Jalkanen Chief Development Officer , Faron Pharmaceuticals


  • Exploring the use of CLEVER-1 antagonist antibody, as a macrophage checkpoint inhibitor to reverse PD-1 inhibitor resistance
  • Insights into dose escalation studies and demonstrating proof of concept in tumor specific expansion cohorts

2:30 pm Macrophage Repolarization is Capable of Inflaming Tumor Microenvironment

  • Igor Feldman Co-Founder & Chief Analytics Officer, Verseau Therapeutics


  • Tumors evolve the ability to induce and maintain a microenvironment capable of shielding it from immune surveillance. Macrophage repolarization is capable of shifting the polarity of the tumor microenvironment away from tolerance and toward an immune attack. Given the prevalence of human tumors highly infiltrated with tolerogenic macrophages, targeting them is a potent strategy to broaden the clinical reach of what was possible with T cell checkpoint inhibitors

3.00pm Afternoon Break & Networking

Modulating Macrophage Phenotype and Function for Enhanced Efficacy of Solid Tumor Treatment

3:30 pm Targeting Tumor Associated Macrophages in Advanced Breast Cancer

  • Jennifer Guerriero Lead Investigator, Brigham and Women’s Hospital, Director, Breast Tumor Immunology Laboratory, Dana- Farber Cancer Institute, Instructor in Medicine, Harvard Medical School,


  • Gain knowledge of the biology, ontology and phenotype of tumor associated macrophages
  • Assess novel immunotherapy strategies aimed at targeting macrophages for anti-cancer therapy
  • Elucidate the diversity of myeloid cells in breast cancer

4:00 pm Panel Discussion: Evaluating the Synergistic Potential of Combination with Other Frontline Treatments to Distinguish the Best Combination Approach


  • Combining macrophage therapy with Radiotherapy
  • Utilizing other small molecules (e.g. PARP inhibitors, STING agonists) with first-in-class antibody targeting the myeloid-specific ILT4 receptor
  • Developing clinical trial strategy to determine which combinations have the most synergistic/additive potential

4:30 pm Preclinical Characterization of IO-108, a Novel LILRB2 Antagonist Antibody for Immunotherapy of Solid Tumors


  • Outlining the LILRB2 biology, therapeutic rationale for development of IO-108, as well as showing the preclinical data characterizing its biological activity

5:00pm Chair’s Closing Remarks & End of Summit